Related Experiment Videos
Skin manifestations in CD4+, CD56+ malignancies
Katell Penven1, Margaret Macro, Véronique Salaun
1Department of Dermatology, Centre Hospitalier Universitaire, Avenue Georges Clemenceau, 14033 Caen Cedex, France.
European Journal of Dermatology : EJD
|April 16, 2003
Summary
CD4+ CD56+ hematologic neoplasms are rare cancers. This study details three cases, highlighting their unique immunophenotype and T-cell rearrangement, with poor treatment outcomes.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- CD4+ CD56+ hematologic neoplasms represent a recently defined category of malignancies.
- These neoplasms present unique diagnostic challenges, particularly when exclusively involving the skin.
Observation:
- The study reports three cases of CD4+ CD56+ malignancies with cutaneous and bone marrow involvement.
- A consistent immunophenotype was noted, characterized by co-expression of CD4 and CD56, and the absence of B and T-cell markers.
- T-cell clonal rearrangement was a significant finding in these cases.
Findings:
- Clinical and pathological features resemble acute leukemia with monocytic differentiation and granulocytic sarcoma.
- The presence of CD56 positivity prompted discussion of natural killer cell proliferations.
- Cytological features like cytoplasmic vacuoles and pseudopodia in blood and bone marrow cells are characteristic.
- CD123 antigen positivity suggests a plasmacytoid dendritic cell proliferation and serves as a marker for cutaneous lesions.
Implications:
- The findings contribute to the understanding and diagnosis of CD4+ CD56+ hematologic neoplasms.
- Early and accurate diagnosis is crucial, especially with exclusive cutaneous involvement.
- Further research into the biology and treatment of these rare neoplasms is warranted.